RMD was sold off in April as supply chain issues weighed on the business’s operations but we still feel these issues will pass and the developer of sleep disorder treatments will return with 10-15% growth over the next 3 years hence the recent pullback is largely an opportunity in our opinion. However, we already have a 6% exposure to this high-quality defensive healthcare stock which we can see rotating between $25 and $35 over the next 6 months, hence we are considering trimming our position if we see another ~$4 upside.
MM will consider reducing RMD around $35
Add To Hit List
